BioWorld

Aug. 8, 2002

View Archived Issues

Narrowing Focus To Three Drugs, EntreMed Makes Reductions

Read More

Changeable Chromosomal Gene Expression Patterns Foretell Fate, Relapse Or Cure In Wilms' Tumor

Read More

Completed Phase III Enrollment Brings Eyetech Rest Of $108.5M

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Feeling Biotech's Money Woes, Targeted Genetics Cuts Back

Tenuous economic conditions have prompted Targeted Genetics Corp. to reduce expenses by eliminating jobs and placing certain projects on the backburner, the company's president and CEO said. (BioWorld Today) Read More